homepage-top-section

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According

The expanded indication for Sprycel is in combination with chemotherapy. It was granted by the regulator following priority review based on the findings of the phase 2 study,

The FDA will review the NDA for KPI-121 0.25%, which is designed to provide temporary relief to the signs and symptoms of dry eye disease, including dry eye

Indian pharmaceutical company Lupin has awarded the licensing rights of its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) programme to AbbVie. The deal gives AbbVie exclusive global

CellforCure is a major French contract development and manufacturing organization engaged in the production of cell and gene therapies in Europe. As per terms of the deal, Novartis

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor,

The divested rights by the UK-based AstraZeneca to Covis Pharma cover markets outside the US and the US royalties for the three over-the-counter (OTC) drugs. In 2017, AstraZeneca

Based in Waltham of Massachusetts, Tesaro is a commercial-stage firm engaged in the development of advanced therapies to treat cancer. As per the terms of the deal, GSK’s

Truxima, a monoclonal antibody (mAb), has been approved to treat adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL) as a single agent.